Immtech: Pafuramidine Trial Gets Fast-Track Status In China (China)
This article was originally published in PharmAsia News
China's State Food and Drug Administration has granted Immtech Pharmaceuticals' application for fast-track status for conducting a Phase III clinical trial involving pafuramidine. Pafuramidine is the company's oral drug candidate for the treatment of Pneumocystis pneumonia, a fungal infection in the lungs that can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. (Click here for more - May Require Paid Subscription
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.